Skip to main content
Medical information Clinical review pending

Genetic Testing

ELAC2 Gene Prostate Cancer Hereditary Type 2 Susceptibility to Genetic Test

The ELAC2 Gene Prostate Cancer Hereditary Type 2 Susceptibility Genetic Test uses Next Generation Sequencing (NGS) to assess genetic risk for prostate cancer. This test helps identify hereditary predispositions, enabling proactive health management, especially for those with a family history.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (typically collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for this test. However, confirm with the laboratory for any specific instructions.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the ELAC2 Gene Prostate Cancer Hereditary Type 2 Susceptibility to Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Men with a family history of prostate cancer
  • ✓Individuals with multiple relatives diagnosed with prostate cancer
  • ✓Men diagnosed with prostate cancer at a young age
  • ✓Individuals considering risk-reducing strategies
  • ✓Family members of individuals with known ELAC2 gene mutations
02

In plain language

What this test helps you understand

Identifies genetic variations in the ELAC2 gene associated with an increased risk of hereditary prostate cancer. Helps individuals and their healthcare providers understand potential susceptibility and make informed decisions about screening and prevention.
The ELAC2 Gene Prostate Cancer Hereditary Type 2 Susceptibility Genetic Test is designed to evaluate an individual's genetic risk for developing prostate cancer. It utilizes advanced Next Generation Sequencing (NGS) technology to analyze the ELAC2 gene, which research has linked to an increased susceptibility to hereditary prostate cancer. Understanding your genetic predisposition can provide valuable information for managing your health proactively.

This test specifically looks for variations within the ELAC2 gene that may indicate a higher risk of prostate cancer. By examining these genetic markers, healthcare providers can gain a clearer picture of an individual's potential susceptibility to this condition.

Consulting with a healthcare professional is crucial for interpreting your test results and understanding the implications for your health management plan.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for this test. However, confirm with the laboratory for any specific instructions.
SampleBlood sample (typically collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) is used to analyze the ELAC2 gene for specific variations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes only the ELAC2 gene and does not assess risk associated with other genes or environmental factors. A negative result does not completely rule out the risk of developing prostate cancer. Genetic testing results should be interpreted by a qualified healthcare professional.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The ELAC2 gene is a gene that research suggests may be linked to an increased risk of developing hereditary prostate cancer when certain variations are present.
This test is generally recommended for men with a strong family history of prostate cancer, those diagnosed at a young age, or individuals with multiple affected relatives.
A positive result indicates the presence of a genetic variation in the ELAC2 gene associated with increased prostate cancer risk. It is important to discuss this with your doctor to understand the implications and next steps.
No, this test does not guarantee you will develop prostate cancer. It identifies an increased genetic susceptibility, but other factors also play a role. Discuss your results with your doctor.
Results are typically reported as a genetic variant report, which should be interpreted by a qualified healthcare professional familiar with genetic testing.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp